Skip to main content
. 2021 Jan 1;11(5):2364–2380. doi: 10.7150/thno.47996

Figure 8.

Figure 8

Endocytosis inhibitor enhances the anti-MM effect of bortezomib in vitro. (A) RPMI 8226 or (B) U266 cells were pretreated with or without bortezomib for 6 h and then cultured with or without dynasore in the presence or absence of 100 μg/mL sEVs for another 24 h, and the cell viability was measured. One representative result in triplicate of three experiments was presented by histograms. Similar results were obtained in three independent experiments. (C) RPMI 8226 or (D) U266 cells were pretreated with or without bortezomib for 6 h and then cultured with or without dynasore in the presence or absence of 100 μg/mL sEVs for another 24 h, apoptotic cells were determined using 7-AAD and Annexin-V staining and flow cytometry. Representative flow cytometry plots are shown. The proportions of live, early apoptotic or late apoptotic and dead cells were analyzed and presented by histograms. One-way ANOVA followed by multiple compressions was used for comparing multiple groups. Error bar, mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.